Public

Environmental and Social Data Sheet

Overview

<table>
<thead>
<tr>
<th>Project Name</th>
<th>MOBIDIAG (EGFF)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Project Number</td>
<td>2019-0062</td>
</tr>
<tr>
<td>Country</td>
<td>Finland</td>
</tr>
<tr>
<td>Project Description</td>
<td>Financing of Mobidiag Oy, an innovative medical diagnostic company based in Finland. The financing will help Mobidiag to develop fast and inexpensive diagnostic tests for infectious diseases.</td>
</tr>
</tbody>
</table>

EIA required: no

Project included in Carbon Footprint Exercise\(^1\): no
(details for projects included are provided in section: “EIB Carbon Footprint Exercise”)

Environmental and Social Assessment

Environmental Assessment

The activities to be financed are research, development and innovation in the medical technology sector, enabling the company to develop further individual diagnostic tests for its proprietary Novodiag platform. The project’s activities are not listed in any of the annexes of the EU Directive 2014/52/EU amending 2011/92/EU. The project will not result in any residual environmental impact as it will be executed in existing and authorised research facilities. Therefore, an Environmental Impact Assessment (EIA) is not required.

The promoter’s practices are in compliance with the relevant national and EU regulations (directive 98/79/EC as amended and applicable good practice quality guidelines and regulations). The promoter maintains adequate internal procedures and management practices and is certified under ISO 13485.

The operating procedures in place are in line with best industry standards and are subjected to regular external audits.

Social Assessment, where applicable

The project, if successful, is expected to lead to important social benefits stemming from its focus on the development of novel diagnostic tests to detect quickly and accurately infectious diseases.

---

\(^1\) Only projects that meet the scope of the Pilot Exercise, as defined in the EIB draft Carbon Footprint Methodologies, are included, provided estimated emissions exceed the methodology thresholds: above 20,000 tons CO2e/year absolute (gross) or 20,000 tons CO2e/year relative (net) – both increases and savings.
Through the R&D activities and investments, the promoter expects to sustain and even increase its current level of highly skilled personnel, while contributing to European scientific innovation, hence fostering and nurturing the vital research community.

**Conclusions and Recommendations**

The project concerns investments in research and development that will be carried out in existing facilities without changing their already authorised scope. An Environmental Impact Assessment (EIA) is therefore not required by EIA Directive 2014/52/EU amending Directive 2011/92/EU. The promoter has an integrated environmental management policy and effective operating procedures in place which are in line with best industry standards.

The research activities undertaken in the project aim to generate new and improved diagnostic tests having a positive impact on the quality of healthcare. Therefore, if the project is successful, it is expected to have a positive social impact.

Considering the above, the project is acceptable for Bank financing in terms of environmental and social aspects.